Glimepiride Evolugen (Glimepiride)

Glimepiride Evolugen is indicated for the oral treatment of adults with type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• As monotherapy in patients with mild to moderate hyperglycemia.
• In combination with metformin when additional glucose lowering is needed.
• As part of a fixed‑dose combination regimen with other oral antidiabetics.
• To improve fasting plasma glucose and post‑prandial glucose levels.
• For use under the supervision of a healthcare professional experienced in diabetes management.

The safety profile of glimepiride includes a range of adverse events that vary in frequency and severity.

Common

• Mild hypoglycemia, especially when meals are skipped or delayed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain due to increased insulin activity.
• Fatigue or weakness.
• Transient elevation of liver enzymes.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions such as rash, itching, or swelling.
• Hematologic abnormalities like leukopenia or thrombocytopenia.
• Acute pancreatitis presenting with abdominal pain.
• Cardiovascular events such as arrhythmia in susceptible patients.

Before initiating glimepiride therapy, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function, as impairment may increase drug exposure.
• Review history of hypoglycemia or adrenal insufficiency.
• Use caution in elderly patients due to heightened sensitivity to glucose lowering.
• Avoid use during pregnancy and lactation unless benefits clearly outweigh risks.
• Monitor blood glucose regularly, especially when initiating or adjusting dose.
• Consider dose reduction when combined with other insulin‑secretagogues.
• Educate patients on recognizing and managing hypoglycemia symptoms.

Glimepiride can interact with various medications, affecting its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.
• Discontinuous alcohol intake, which can potentiate hypoglycemia.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can increase blood glucose and counteract drug effect.
• ACE inhibitors or ARBs, requiring monitoring of renal function and electrolytes.
• Anticoagulants such as warfarin, as glimepiride may alter INR values.
• Other insulin‑secretagogues, requiring close glucose monitoring.
• Medications that affect renal clearance, necessitating dose adjustments.